Patients with Fabry Disease after Enzyme Replacement Therapy Dose Reduction Versus Treatment Switch

Because of the shortage of agalsidase-beta in 2009, many patients with Fabry disease were treated with lower doses or were switched to agalsidase-alfa. This observational study assessed end-organ damage and clinical symptoms during dose reduction or switch to agalsidase-alfa. A total of 105 adult pa...

Cijeli opis

Spremljeno u:
Bibliografski detalji
Glavni autori: Weidemann, Frank, Krämer, Johannes, Duning, Thomas, Lenders, Malte, Canaan-Kühl, Sima, Krebs, Alice, González, Hans Guerrero, Sommer, Claudia, Üçeyler, Nurcan, Niemann, Markus, Störk, Stefan, Schelleckes, Michael, Reiermann, Stefanie, Stypmann, Jörg, Brand, Stefan-Martin, Wanner, Christoph, Brand, Eva
Format: Artigo
Jezik:Inglês
Izdano: American Society of Nephrology 2014
Teme:
Clinical Research
Online pristup:https://ncbi.nlm.nih.gov/pmc/articles/PMC3968503/
https://ncbi.nlm.nih.gov/pubmed/24556354
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1681/ASN.2013060585
Oznake: Dodaj oznaku
Bez oznaka, Budi prvi tko označuje ovaj zapis!

Similar Items